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ImmunogenicityBackground: A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetraTM, Sanofi Pasteur;
IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and
Yamagata) was approved in Europe in 2016 for individuals aged  3 years. This study examined the effi-
cacy and safety of IIV4 in children aged 6–35 months.
Methods: This was a phase III randomised controlled trial conducted in Latin America, Asia, Africa, and
Europe during the Northern Hemisphere 2014/2015 and 2015/2016 and Southern Hemisphere 2014
and 2015 influenza seasons. Healthy children aged 6–35 months not previously vaccinated against influ-
enza were randomised to receive two full doses 28 days apart of IIV4, placebo, the licensed trivalent split-
virion inactivated vaccine (IIV3), an investigational IIV3 containing a B strain from the alternate lineage.
The primary objective was to demonstrate efficacy against influenza illness caused by any strain or
vaccine-similar strains.
Results: The study enrolled 5806 participants. Efficacy, assessed in 4980 participants completing the
study according to protocol, was demonstrated for IIV4. Vaccine efficacy was 50.98% (97% CI, 37.36–
61.86%) against influenza caused by any A or B type and 68.40% (97% CI, 47.07–81.92%) against influenza
caused by vaccine-like strains. Safety profiles were similar for IIV4, placebo, and the IIV3s, althoughSantos),
adopou-
an), Iris.
1 Abbreviations: CI, confidence interval; GMT, geom
glutinin; HAI, hemagglutination inhibition; IIV3-1, in
virion inactivated vaccine containing the B lineage (V
the World Health Organization; IIV3, split-virion
licensed trivalent split-virion inactivated vaccine
(Yamagata) recommended by the World Health Org
split-virion inactivated influenza vaccine; NA, neu
transcription-polymerase chain reaction; VE, vaccine
Organization.
S. Pepin et al. / Vaccine 37 (2019) 1876–1884 1877injection-site reactions were slightly more frequent for IIV4 than placebo.
Conclusions: IIV4 was safe and effective for protecting children aged 6–35 months against influenza ill-
ness caused by vaccine-similar or any circulating strains.
Clinical trial registration: EudraCT no. 2013-001231-51.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Influenza is a highly contagious viral infection and a significant
burden especially for children due to an increased risk for severe
illness and hospitalisation [1,2]. Although influenza A has histori-
cally been considered more important, influenza B is now known
to be a significant cause of influenza-related illness, hospitalisa-
tion, and death [3] and to cause epidemics every 2–4 years [3,4].
Influenza B is a particular concern in young children in whom it
causes a disproportionate amount of severe illness and hospitalisa-
tion [3,5].
In the 1980s, influenza B viruses diverged into two immunolog-
ically distinct lineages, Victoria and Yamagata, which now co-
circulate worldwide [6]. Because trivalent influenza vaccines con-
tain only a single B-lineage strain and because circulation varies
between seasons and regions, differences between the vaccine
and dominant circulating B-lineages are common [7,8]. Due to lim-
ited cross-lineage protection [9,10], especially in young children
[11], quadrivalent influenza vaccines containing both B lineages
may reduce the risk of influenza illness and its associated morbid-
ity and mortality [12].
A quadrivalent split-virion inactivated influenza vaccine (IIV41;
VaxigripTetraTM, Sanofi Pasteur) has been available in Europe since
2016 for individuals aged  3 years. Phase III clinical trials in indi-
viduals  3 years demonstrated that IIV4 was as immunogenic as
the comparator trivalent inactivated influenza vaccine (IIV3) for each
of the three shared influenza strains and superior for the additional B
strain [13–16]. These trials also showed that IIV4 has a similar safety
and reactogenicity profile as the licensed IIV3 (Vaxigrip, Sanofi
Pasteur).
Because few studies had reported efficacy of inactivated
influenza vaccines in very young children, in 2012, the World
Health Organization (WHO) stated that they had only moderate
confidence in their efficacy for this population [17]. To assess
IIV4 in young children and to help reduce this evidence gap, we
performed a phase III placebo-controlled clinical trial in which
the primary objective was to demonstrate efficacy in children aged
6–35 months. Importantly, the vaccine used in this study con-
tained a full dose of antigen (15 mg hemagglutinin [HA] per strain)
rather than a half dose (7.5 mg HA per strain), which has been used
in this age group for >30 years. A half dose of antigen was originally
intended to reduce the risk of convulsions associated with earlier
whole-virus influenza vaccines [18], but more recent findings
suggest that a full dose can be used in children <3 years to
improve immunogenicity without increasing fever or other reac-
tions [19–21].etric mean titre; HA, hemag-
vestigational trivalent split-
ictoria) not recommended by
inactivated vaccine; IIV3-2,
containing the B lineage
anization; IIV4, quadrivalent
raminidase; RT-PCR, reverse
efficacy; WHO, World Health2. Materials and methods
2.1. Study design
This was a phase III, randomised, placebo-controlled trial con-
ducted between March 2014 and July 2016 at 49 centres in Asia,
Latin America, Europe, and Africa (EudraCT no. 2013-001231-
51).2 The study included healthy children aged 6–35 months who
had not been previously vaccinated for or infected with influenza
according to participants’ parents or guardians. Children aged < 24 -
months had to be born at full term (37 weeks) or with a birth
weight  2.5 kg. Further exclusion criteria are listed in Table S1.
The primary objective was to demonstrate the clinical efficacy of
two full doses (15 mg HA/strain) of IIV4 to prevent laboratory-
confirmed influenza illness caused by any influenza A or B types or
caused by vaccine-similar strains. Key secondary objectives were
to demonstrate non-inferiority of hemagglutination inhibition
(HAI) geometric mean titres (GMTs) for strains shared by IIV4 and
IIV3; demonstrate superiority of HAI GMTs for B-lineage strains
not shared between IIV4 and IIV3; and describe the immunogenicity
and safety of all vaccines. The study design, including the influenza
seasons, countries, randomisation schemes, participants included
in the analyses for the different outcomes, and data monitoring are
summarised in Fig. 1.
During the efficacy evaluation period, participants were ran-
domised to receive two 0.5-ml doses 28 days apart (window
+7 days) of IIV4 containing the WHO-recommended A(H3N2), A
(H1N1), B/Yamagata-lineage, and B/Victoria-lineage strains; an
investigational IIV3 containing the WHO-recommended A strains
and a strain from the B lineage not recommended by the WHO
(Victoria) (IIV3-1); the licensed IIV3 containing the WHO-
recommended A and B (Yamagata lineage) strains (IIV3-2); or pla-
cebo (saline). Efficacy was assessed only in participants vaccinated
with IIV4 or placebo, whereas blood samples were taken for
immunogenicity testing from all participants 28 days after the sec-
ond vaccination.
A randomly selected subset of participants who had received
IIV4 or placebo during the 2014/2015 season was asked to return
during the 2015/2016 season to be vaccinated with IIV4 (revacci-
nation period). Those who had received IIV4 during the
2014/2015 season were vaccinated with a single 0.5-ml dose of
IIV4, whereas those who had received placebo were vaccinated
with two 0.5-ml doses of IIV4 28 days apart (window ±14 days).
Blood samples were taken for immunogenicity testing 28 days
after each vaccination.2.2. Randomisation and blinding
Randomisation lists were generated with the permuted block
method and were communicated via an interactive voice or web-
response system. The study was single (observer)-blinded for the
IIV4 and placebo groups and, due to differences in study proce-
dures, open label for IIV3-1 and IIV3-2.2 The protocol for this clinical trial is available at https://www.clinicaltrialsregister.
eu/.
Fig. 1. Study design. The efficacy evaluation period was conducted in three cohorts: during the SH 2014 season in South Africa and The Philippines, participants were
randomised 1:1 to IIV4 or placebo; during the NH 2014/2015 season in France, Greece, Italy, Spain, and Honduras, participants were randomised 2:2:1:1 to IIV4, placebo, IIV3-
1, or IIV3-2; and during the NH 2014/2015 (Dominican Republic), SH 2015 (Philippines), and NH 2015/2016 (Italy, Spain, and Romania) seasons, participants were
randomised 1:1 to IIV4 or placebo. During the revaccination period, a randomly selected subset of participants who had been vaccinated with IIV4 or placebo during the NH
2014/2015 season were invited to come back the following (2015/2016) season to be vaccinated with IIV4. Influenza cases and efficacy data were reviewed periodically by an
independent data monitoring committee, and blinded safety data were reviewed by an internal safety management team. Abbreviations: AE, adverse event; HAI,
hemagglutination inhibition; IIV3-1, trivalent influenza vaccine containing the B-lineage strain not recommended by the World Health Organization; IIV3-2, trivalent
influenza vaccine containing the B-lineage strain recommended by theWorld Health Organization; IIV4, quadrivalent split-virion inactivated influenza vaccine; ILI, influenza-
like illness; NH, Northern Hemisphere; Rep, Republic; SH, Southern Hemisphere.
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The study was approved by the independent ethics committee
or institutional review board for each study site and was conducted
in accordance with Good Clinical Practice and the Declaration of
Helsinki. Written informed consent was provided by the parents
or legal representatives of all children participating in this trial.
2.4. Vaccines
All vaccines were thimerosal-free, inactivated, split-virion, and
contained 15 lg of HA from each strain per 0.5-ml dose. Vaccines
and placebo were presented in 0.5-ml prefilled syringes and were
administered by intramuscular or deep subcutaneous injection
into the deltoid region or the thigh. Vaccine formulations and
strains used in the study are summarised in Table S2.
2.5. Detection of influenza and analysis of similarity to vaccine strains
The occurrence of influenza-like illness was followed from
14 days after the second vaccine dose until the end of Octoberfor Asia and Africa and the end of April for Europe and Latin Amer-
ica. Participants were considered to have influenza-like illness if
they had a fever 38 C lasting 24 h concurrently with cough,
nasal congestion, rhinorrhoea, pharyngitis, otitis, vomiting, or diar-
rhoea. For participants diagnosed with influenza-like illness, a
nasopharyngeal swab was taken for laboratory confirmation of
influenza within 10 days after onset.
Nasopharyngeal swab samples from subjects with influenza-
like illness were used to inoculate and infect influenza virus-
susceptible tissue culture cell lines. Influenza positive cultures
were confirmed by direct immunofluorescence techniques with
influenza type-specific (i.e., for influenza A and influenza B) anti-
bodies. For culture confirmation of influenza, three different cul-
ture cell lines were utilised for each nasopharyngeal sample:
classic influenza A and B culture using Madin-Darby canine kidney
cells; classic influenza A and B culture using rhesus monkey kidney
cells; and R Mix (a mixed monolayer of human A549 lung carci-
noma and mink lung cells).
Clinical samples collected during the study period underwent
an extraction procedure to isolate the viral RNA from nasopharyn-
geal swabs prior to testing. The initial molecular test was a reverse
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(eSensor Respiratory Viral Panel, GenMark) to determine if influ-
enza A, influenza A H1 seasonal subtype, influenza A H3 seasonal
subtype, influenza A 2009 H1N1 subtype, or influenza B were pre-
sent in the clinical sample.
For samples that were positive for influenza based on viral cul-
ture or RT-PCR, further testing by Sanger sequencing of the HA and
neuraminidase (NA) full-gene segments was performed to identify
the specific type or sub-type of the influenza strain. For genetic
sequencing of HA and NA gene segments, total nucleic acid was
extracted from the specimen/samples on an automated extraction
system. Regions of both HA and NA genes were amplified by RT-
PCR using H1N1, H3N2 and B strain-specific primers. Amplified
products were purified by plate filtration, and cycle sequencing
reactions were performed on purified amplicons using fluores-
cently labelled dideoxy terminators. Cycle sequencing reaction
products were purified by precipitation and analysed by agarose
gel electrophoresis on an automated genetic analyser.
The raw genetic sequence of each positive sample was com-
pared with a database of known sequences corresponding to the
vaccine and major circulating strains from 2005 up to the time of
testing. Upon completion of sequencing runs, consensus sequences
were compared to the Sanofi Pasteur reference BLAST database to
determine closely related sequences. The best match had to be
95% alignment length and 99% identity. If a sequence did not
meet these criteria, it was used as a query against the current ver-
sion of National Center for Biotechnology Information Influenza
Virus Resource Database.
The strain responsible for laboratory-confirmed influenza was
based on the Sanger sequencing results of the full HA gene,
although if the RT-PCR results indicated A/H1N1 2009 pandemic
influenza, the strain was considered to be A/California/7/2009.
The strain responsible for a laboratory-confirmed influenza case
was considered as similar to a strain contained in the vaccine if
the best match strain was the same as any of the vaccine strains.2.6. HAI titres
Serum HAI titres were measured as described previously [22]
for a randomly selected subset of participants included in the effi-
cacy evaluation period (see Fig. 1) and for all participants included
in the revaccination period. Seroconversion was defined as a HAI
titre <10 on day 0 and a HAI titre 40 measured 28 days after
the last vaccination. A significant increase was defined as a HAI
titre 10 on day 0 and a 4-fold increase from baseline in HAI titre
28 days after the last vaccination.2.7. Solicited reactions and adverse events
Solicited reactions were collected by parents and legal guar-
dians, and unsolicited adverse events were recorded by investiga-
tors (see Fig. 1 for subsets included). Solicited injection-site
reactions included tenderness for participants aged 6–23 months;
pain for participants 24–35 months; and erythema, swelling,
induration, and ecchymosis for all participants. Solicited systemic
reactions included vomiting, abnormal crying, drowsiness, loss of
appetite, and irritability for participants aged 6–23 months; head-
ache, malaise, myalgia, and shivering for participants aged 24–
35 months; and fever for all participants. Investigators also
recorded serious adverse events and adverse events of special
interest up to 6 months after each injection. Adverse events and
serious adverse events were recorded according to International
Conference for Harmonization guidelines [23].2.8. Statistical analysis
The co-primary outcomes were vaccine efficacy (VE) in prevent-
ing laboratory-confirmed influenza caused by (i) any A or B strain
and (ii) vaccine-similar strains. Both were assessed in all ran-
domised participants in the IIV4 and placebo groups without rele-
vant protocol violations and according to the vaccine to which they
were randomised. Sensitivity analysis was performed in the full set
of randomised patients who received two doses of vaccine. VE was
calculated as 100%  (1  [number of confirmed influenza cases in
the IIV4 group/total number of participants in the IIV4 group]/
[number of influenza cases in the placebo group/total number of
participants in the placebo group]). Confidence intervals (CIs) for
VE were calculated by an exact method assuming a binomial distri-
bution of the number of cases in each vaccine group conditional on
the total number of cases. The co-primary endpoints were assessed
using a one-sided 0.015 nominal alpha, resulting in a two-sided
97% CI. For each of the co-primary outcomes, efficacy was consid-
ered demonstrated if the lower-bound of the 97% CI for the corre-
sponding VE was >20%. The primary objective was considered to
have been met if efficacy was demonstrated for either of the co-
primary outcomes.
Approximately 553 evaluable influenza cases were needed to
provide approximately 80% power to draw a conclusion of VE (pri-
mary objective) assuming that the true VE for IIV4 is 45% against
vaccine-similar influenza strains and 0% against other strains; an
adjusted one-sided type I error rate of 0.01247; a lower-bound of
the CI of VE >20% for at least one primary outcome; and an alloca-
tion ratio of IIV4 to placebo of 1:1. Considering an overall influenza
attack rate of 9% for the occurrence of an influenza case in the pla-
cebo group and 90% of enrolled participants evaluable for the pri-
mary outcome, a total of 8536 participants were estimated to be
needed to be enrolled for influenza surveillance to reach the 553
expected evaluable influenza cases.
Non-inferiority of HAI titres was assessed according to the vac-
cine received in randomised participants who completed the vacci-
nation schedule, had a blood sample drawn 28–35 days after the
last dose, and completed the efficacy evaluation period according
to protocol. For each strain, non-inferiority was demonstrated if
the two-sided 95% CI of the ratio of the geometric mean HAI titre
(GMT) between IIV4 and IIV3 containing the same B-lineage strain,
calculated using a normal approximation of log-transformed titres,
was >2/3. Superiority was assessed in randomised participants
who received at least one dose of vaccine and had a blood sample
drawn 28–35 days after the last dose. For each B strain, superiority
was demonstrated if the two-sided 95% CI of the ratio of the GMT
between IIV4 and IIV3 containing the alternate B-lineage strain,
calculated using a normal approximation of log-transformed titres,
was >1.
There were to be approximately 464 subjects assessed for HAI
immunogenicity in the IIV4 group and 232 subjects in each IIV3
group. This was to produce an overall power of 90% to demon-
strate: (a) non-inferiority of IIV4 vs. IIV3 in terms of HAI GMTs with
a one-sided alpha level of 2.5%, a non-inferiority margin of 1.5, a
theoretical ratio of 1:1 between groups, assuming a standard devi-
ation of log10-transformed titres of 0.6 for A strains and 0.5 for B
strains, and 80% subjects evaluable; and (b) superiority of IIV4 vs.
each IIV3 group for the B-lineage strain it did not contain assuming
that the IIV4 induced at least a 2-fold increase in the IIV3 response
to the B strain it did not contain, a standard deviation of log10-
transformed titres of 0.5, and 90% subjects evaluable.
Statistical analysis was performed by Sanofi Pasteur (Marcy
L’Etoile, France) using SAS version 9.4 (SAS Institute, Cary, NC,
USA). Missing data were not replaced.
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Two interim analyses by an independent data monitoring com-
mittee were planned to determine if efficacy had been demon-
strated. The first was conducted when 200 confirmed influenza
cases had been detected. The second, planned for when 375 con-
firmed influenza cases had been detected, was not conducted
because efficacy was demonstrated at the first interim analysis.
Enrolment was to be stopped at either interim analysis if the pri-
mary objective of efficacy was met, if the predictive power to
demonstrate the primary objective at the end of the ongoing sea-
son was high, or if the probability to demonstrate the primary
objective at the end of the trial was too low.3. Results
3.1. Participants
The study enrolled 5806 participants aged 6 to 35 months of
which 5805 were randomised to receive two injections 28 days
apart of IIV4 (n = 2721), placebo (n = 2715), IIV3-1 (n = 183), or
IIV3-2 (n = 186) (Fig. 2). The study was conducted over four influ-
enza seasons (Southern Hemisphere 2014 and 2015 and Northern
Hemisphere 2014/2015 and 2015/2016) so that enrolment
spanned 18 months from March 12, 2014 to December 4, 2015.
Enrolment was stopped before the planned study size (8536 partic-
ipants) was reached because efficacy was demonstrated during a
planned interim analysis. A random subset of participants who
had received IIV4 (n = 213) or placebo (n = 41) during the efficacy
evaluation period were vaccinated with IIV4 the following season.Fig. 2. Participant disposition. Abbreviations: AE, adverse event; IIV3-1, trivalent influen
Organization; IIV3-2, trivalent influenza vaccine containing the B-lineage strain recomm
influenza vaccine; SAE, serious adverse event.Sex, age, and prevalence of at-risk conditions were similar in the
four study groups (Table 1). Regions and ethnicities were similar
for the IIV4 and placebo groups but different from the IIV3 groups
as a result of the study design (see Fig. 1). No participants left the
study due to a vaccine-related adverse event.
3.2. Efficacy vs. laboratory-confirmed influenza illness
Of the 5436 participants in the IIV4 and placebo groups who
completed the efficacy evaluation period, 456 were not included
in the per-protocol efficacy analysis because of protocol violations
or deviations. Thus, efficacy was assessed in 4980 participants.
Laboratory-confirmed influenza illness was detected in 365 partic-
ipants, including 120 (4.8%) in the IIV4 group and 245 (9.8%) in the
placebo group. Influenza was due to vaccine-similar strains for 100
of the 365 participants with laboratory-confirmed illness (24 for
IIV4 and 76 for placebo). By strain, confirmed influenza cases were
most commonly due to influenza B (n = 164) and A/H3N2 (n = 156).
Influenza A/H1N1 was relatively uncommon (n = 55). The strains
detected and their similarity to the vaccine strains are listed in
Table S3.
The primary objective of efficacy was demonstrated for IIV4,
with a VE vs. influenza due to any A or B type of 50.98% (97% CI,
37.36–61.86%) and vs. influenza due to a vaccine-like strain of
68.40% (97% CI, 47.07–81.92%) (Table 2). Results were similar when
assessed in the full set of participants vaccinated with two doses of
vaccine (Table S4). VE values for IIV4 were also similar when calcu-
lated separately for RT-PCR-confirmed influenza and culture-
confirmed influenza and when analysed separately for influenza
A, A(H1N1), A(H3N2), B, and B/Yamagata, although not for B/Victo-
ria (Table 2). For the four influenza seasons included, VE rangedza vaccine containing the B-lineage strain not recommended by the World Health
ended by the World Health Organization; IIV4, quadrivalent split-virion inactivated
Table 1
Participant demographics and baseline characteristics.
Characteristic IIV4 Placebo IIV3-1 IIV3-2
N = 2721 N = 2715 N = 183 N = 186
Sex, n (%)
Male 1388 (51.0) 1425 (52.5) 94 (51.4) 98 (52.7)
Female 1333 (49.0) 1209 (47.5) 89 (48.6) 88 (47.3)
Age in months, mean ± SD 19.7 ± 8.4 19.8 ± 8.4 19.7 ± 8.4 19.3 ± 8.1
At risk for influenza-related complicationsa, n (%) 30 (1.1) 30 (1.1) 3 (1.6) 3 (1.6)
Ethnicity, n (%)
White 505 (18.6) 507 (18.7) 76 (41.5) 76 (40.9)
Asian 1504 (55.3) 1504 (55.4) 0 (0.0) 3 (1.6)
Black or African American 261 (9.6) 252 (9.3) 3 (1.6) 2 (1.1)
American Indian b or Alaska Native 207 (7.6) 205 (7.6) 102 (55.7) 102 (54.8)
Native Hawaiian or Pacific Islander 0 (0.0) 1 (<0.1) 0 (0.0) 0 (0.0)
Region, n (%)
Africa 251 (9.2) 249 (9.2) – –
Asia 1498 (55.1) 1501 (55.3) – –
Europe 528 (19.4) 523 (19.3) 81 (44.3) 84 (45.2)
Latin America 444 (16.3) 442 (16.3) 102 (55.7) 102 (54.8)
Values are for all randomised participants. Abbreviations: IIV3-1, investigational trivalent split-virion inactivated vaccine containing the B lineage (Victoria) not recom-
mended by the World Health Organization; IIV3-2, licensed trivalent split-virion inactivated vaccine containing the B lineage (Yamagata) recommended by the World Health
Organization; IIV4, quadrivalent split-virion inactivated influenza vaccine; SD, standard deviation.
a Participants were considered to be at risk for influenza-related complications if they had chronic respiratory, heart, renal, metabolic, or haematological disorders.
b Latin American participants were classified as American Indian.
Table 2
Efficacy of the quadrivalent influenza vaccine by laboratory confirmation method and strain.
IIV4 Placebo
n (%) n (%)
Outcome N = 2489 N = 2491 Vaccine efficacy
Primary outcome % (97% CI)
Laboratory-confirmed influenza illness caused by
Any influenza A or B type 120 (4.82) 245 (9.84) 50.98 (37.36; 61.86)
Vaccine-similar strains 24 (0.96) 76 (3.05) 68.40 (47.07; 81.92)
Secondary outcomes % (95% CI)
RT-PCR-confirmed influenza illness caused by
Any influenza A or B type 118 (4.74) 243 (9.76) 51.40 (39.20, 61.33)
Vaccine-similar strains 24 (0.96) 76 (3.05) 68.40 (49.42, 80.91)
Culture-confirmed influenza illness
Caused by any influenza A or B type 91 (3.66) 214 (8.59) 57.44 (45.36, 67.07)
Caused by vaccine-similar strains 22 (0.88) 74 (2.97) 70.25 (51.56, 82.40)
Laboratory-confirmed influenza illness by strain
Any influenza A 65 (2.61) 147 (5.90) 55.75 (40.35, 67.47)
A(H1N1) 11 (0.44) 44 (1.77) 74.98 (50.77, 88.35)
A(H3N2) 53 (2.13) 103 (4.13) 48.50 (27.59, 63.75)
Any influenza B 58 (2.33) 106 (4.26) 45.24 (23.88, 60.94)
B/Victoria lineage 12 (0.48) 20 (0.80) 39.95 (28.98, 73.24)
B/Yamagata lineage 26 (1.04) 63 (2.53) 58.70 (33.81, 74.90)
Values are for participants with efficacy data completing the efficacy evaluation period according to protocol. Abbreviations: CI, confidence interval; IIV4, quadrivalent split-
virion inactivated influenza vaccine; RT-PCR, reverse transcription-polymerase chain reaction.
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was 45.8% and 57.9% (Table S5).
3.3. Immunogenicity
At baseline, most participants were seronegative for each vac-
cine strain in IIV4 (Tables S6 and S7), with the exception of partic-
ipants in Asia during the Southern Hemisphere 2014 season of
whom 49.6% were seronegative. After vaccination with two doses
of IIV4 (day 56), for each strain, <2% of participants remained
seronegative. Post-vaccination HAI GMTs ranged from 445 to 819
for A(H1N1), 517 to 1901 for A(H3N2), 416 to 1183 for B/Victoria,
and 783 to 1610 for B/Yamagata. Geometric mean post-/pre-
vaccination ratios of HAI titres ranged from 34.9 to 61.3 for A
(H1N1), 32.7 to 63.4 for A(H3N2), 70.4 to 122 for B/Victoria, and68.2 to 275 for B/Yamagata. Rates of seroconversion or significant
increase in titre were 87% for all strains.
Irrespective of the serological status at baseline, HAI antibody
titres increased markedly after two injections of IIV4, although
HAI GMTs were higher in participants with detectable titres
(10) at baseline than in participants with undetectable titres
(<10) (2149 vs. 408 for A(H1N1), 3632 vs. 585 for A(H3N2), 3986
vs. 562 for B/Victoria, and 1698 vs. 870 for B/Yamagata) (Table S8).
Non-inferiority of post-vaccination HAI titres for IIV4 was
demonstrated for both A strains when compared to the pooled
IIV3s (Table 3). Non-inferiority was also demonstrated for B/Yam-
agata when compared to the IIV3 containing the same B strain
(IIV3-2), although not for B/Victoria when compared to the IIV3
containing the same B strain (IIV3-1). However, for both B strains,
superiority was demonstrated for IIV4 when compared to IIV3 con-
Table 3
Non-inferiority and superiority of antibody responses induced by the quadrivalent influenza vaccine vs. trivalent comparators.
Analysis/strain IIV4 IIV3 Ratio of GMTs (IIV4/IIV3) Non-inferior/ superior
N Day 56 HAI GMT (95% CI) N Day 56 HAI GMT (95% CI)
Non-inferioritya
A(H1N1) 300 650 (549, 769) 320c 629 (530, 746) 1.03 (0.81, 1.31) Yes
A(H3N2) 300 1075 (917, 1261) 320c 989 (845, 1158) 1.09 (0.87, 1.36) Yes
B/Victoria lineage 300 593 (519, 678) 152d 806 (657, 988) 0.74 (0.58, 0.93) No
B/Yamagata lineage 300 997 (863, 1153) 168e 983 (824, 1172) 1.01 (0.80, 1.28) Yes
Superiorityb
B/Victoria lineage 341 623 (550, 706) 179e 10.0 (8.26, 12.1) 62.33 (50.04, 77.64) Yes
B/Yamagata lineage 341 1010 (885, 1153) 171d 39.9 (31.2, 51.0) 25.3 (19.63, 32.62) Yes
Non-inferiority was demonstrated if the two-sided 95% CI of the ratio of the HAI GMT between IIV4 and that of the comparator IIV3, calculated using a normal approximation
of log-transformed titres, was >2/3. Superiority was demonstrated if the two-sided 95% CI of the ratio of the HAI GMT between IIV4 and that of the comparator IIV3, calculated
using a normal approximation of log-transformed titres, was >1. Abbreviations: CI, confidence interval, GMT, geometric mean titre; HAI, hemagglutination inhibition, IIV3,
trivalent inactivated split-virion influenza vaccine; IIV4, quadrivalent inactivated split-virion influenza vaccine.
a The primary analysis for non-inferiority was performed in all randomised participants who completed the vaccination schedule, had blood sample drawn after the last
dose, and completed the efficacy evaluation period according to protocol.
b The primary analysis of superiority was performed in all randomised participants who received at least one dose of vaccine and had a blood sample drawn after the last
dose.
c Comparator was pooled IIV3s (IIV3-1 and IIV3-2).
d Comparator was IIV3-1 (investigational IIV3 containing the B/Victoria lineage).
e Comparator was IIV3-2 (licensed IIV3 containing the B/Yamagata lineage).
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the non-inferiority and superiority analyses were repeated in alter-
nate data sets (Table S9).
During the revaccination period, HAI GMTs at baseline (day
365) were higher in participants who had been vaccinated with
IIV4 than in those who had been vaccinated with placebo
(Fig. S1). After one dose of vaccine (day 393), HAI GMTs for each
strain were at least four-fold higher in participants who had previ-
ously received IIV4 than in those who had previously received
placebo.3.4. Safety and reactogenicity
Except for a higher proportion of participants reporting solicited
injection-site reactions in the IIV4 group (39.9% [95% CI, 37.5–
42.4%]) than in the placebo group (31.9% [95% CI, 29.6–34.2%]),
proportions reporting solicited reactions and adverse events were
similar for the IIV4, IIV3, and placebo groups (Tables 4, S10, and
S11). A single vaccine-related serious adverse event (benign febrile
seizure) was reported for a participant vaccinated with IIV4. The
event was secondary to an upper respiratory tract infection, did
not lead to study discontinuation, and the participant recovered.Table 4
Adverse events and solicited reactions.
Event IIV4
n/N % (95% CI)
Immediate unsolicited adverse event (<30 min) 1/1614 <0.1 (0.0,
Vaccine-related 1/1614 <0.1 (0.0,
Solicited reaction  7 days after vaccination 1017/1592 63.9 (61.5
Injection-site 635/1591 39.9 (37.5
Systemic 772/1592 48.5 (46.0
Unsolicited adverse event  28 days after vaccination 1044/1614 64.7 (62.3
Vaccine-related 91/1614 5.6 (4.6, 6
Leading to study discontinuation 3/1614 0.2 (0.0, 0
Serious adverse event  180 days after vaccination 68/1614 4.2 (3.3, 5
Deatha 4/1614 0.2 (0.1, 0
Adverse event of special interestb 29/2718 1.1 (0.7, 1
Values are for all participants who received at least one dose of vaccine or placebo. Abb
vaccine, IIV4, quadrivalent inactivated split-virion influenza vaccine.
a None of the deaths were considered vaccine-related.
b Included anaphylaxis, Guillain-Barre syndrome, encephalitis/myelitis, neuritis, febri4. Discussion
This randomised, placebo-controlled study confirmed the clini-
cal efficacy of two full doses of IIV4 (15 mg HA/strain) for prevent-
ing influenza in children aged 6–35 months. Efficacy was
demonstrated against vaccine-similar strains as well as against
any strain, even though only about one-quarter of confirmed infec-
tions were due to vaccine-similar strains. The level of efficacy
observed here is similar to that reported for another full-dose inac-
tivated quadrivalent influenza vaccine in this same age group [24].
Together, the results provide convincing evidence that inactivated
quadrivalent influenza vaccines are effective at preventing influ-
enza in children aged 6–35 months.
This study also showed that a full dose of IIV4 could be safely
administered to young children. With the exception of more fre-
quent injection-site reactions with IIV4 than with placebo, the
overall safety profile for IIV4 appeared similar to placebo and
IIV3. This agrees with other studies showing that a full dose of anti-
gen can be used to increase the immune response to influenza vac-
cines in young children without adversely affecting safety [19–
21,24,25]. Furthermore, adding a fourth strain and using a full dose
of antigen (15 mg HA/strain) appeared acceptable for this age
group.Placebo Pooled IIV3
n/N % (95% CI) n/N % (95% CI)
0.3) 2/1612 0.1 (0.0, 0.4) 1/367 0.3 (0.0, 1.5)
0.3) 1/1612 <0.1 (0.0, 0.3) 0/367 0.0 (0.0, 1.0)
, 66.2) 921/1595 57.7 (55.3, 60.2) 216/362 59.7 (54.4, 64.8)
, 42.4) 508/1593 31.9 (29.6, 34.2) 124/361 34.3 (29.5, 39.5)
, 51.0) 741/1595 46.5 (44.0, 48.9) 180/362 49.7 (44.5, 55.0)
, 67.0) 1079/1612 66.9 (64.6, 69.2) 261/367 71.1 (66.2, 75.7)
.9) 96/1612 6.0 (4.9, 7.2) 7/367 1.9 (0.8, 3.9)
.5) 0/1612 0.0 (0.0, 0.2) 0/367 0.0 (0.0, 1.0)
.3) 78/1612 4.8 (3.8, 6.0) 14/367 3.8 (2.1, 6.3)
.6) 1/1612 <0.1 (0.0, 0.3) 0/367 0.0 (0.0, 1.0)
.5) 31/2711 1.1 (0.8, 1.6) 1/367 0.3 (0.0, 1.5)
reviations: CI, confidence interval, IIV3, trivalent inactivated split-virion influenza
le convulsions, non-febrile convulsions, thrombocytopenia, and vasculitis.
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fying a clear threshold for protection has been difficult, especially
for young children [26,27]. Because of this and to help strengthen
the evidence base supporting efficacy of inactivated influenza vac-
cines in very young children, the study focused on demonstrating
efficacy, with immunogenicity as a secondary and supporting end-
point. The study demonstrated that IIV4 induced high HAI anti-
body titres in this population and that it provided superior titres
for the added B-lineage strain and non-inferior titres vs. IIV3 for
all shared strains, except for B/Victoria. This lack of non-
inferiority for the B/Victoria strain does not appear to be a general
feature of IIV4 because non-inferiority against all vaccine strains
has been demonstrated for individuals aged 3 years [22,28].
Whether this unexpected finding will prove to be common for very
young children will require further study.
This study was designed to include unprimed young children.
According to parents and guardians, the participants had not been
previously vaccinated for influenza or infected with influenza
virus. Nevertheless, depending on the region and season, up to half
of the participants had detectable baseline HAI titres for each
strain, suggesting that they had, in fact, been exposed to influenza
viruses. As expected, post-vaccination titres were higher in these
participants, although the IIV4 was highly immunogenic even in
participants without detectable baseline antibodies.
The revaccination portion of the study revealed that the anti-
body titres induced by a single dose of IIV4 increased when the
participants had received IIV4 the previous season. This indicates
that IIV4 could adequately prime this population. It also suggests
that the two-dose schedule currently recommended for vaccinat-
ing unprimed children aged <9 years [29] should be continued
for the full dose of IIV4.
A major strength of this study was its representativeness. It was
a large study conducted over a wide geographical area in both
hemispheres and over several influenza seasons. The study was,
however, limited by the vaccine strains that circulated. During
the four seasons included, influenza A(H3N2) and B/Yamagata
strains dominated. Thus, efficacy could be demonstrated against
the A/H1N1, A/H3N2, and B/Yamagata strains but not against the
B/Victoria strain. Efficacy of IIV4 against the B/Victoria strain will
have to be established in further studies.
In conclusion, this study showed that IIV4 safely protected chil-
dren aged 6–35 months against influenza illness. By including a
second B-lineage strain, IIV4 should provide additional protection
beyond IIV3, irrespective of which B lineage circulates during a
given season or region. As IIV4 gradually replaces IIV3 globally, it
may help further reduce influenza-associated morbidity and mor-
tality in young children.Acknowledgments
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